Ron Goeree
McMaster University
Health careRandomized controlled trialIntensive care medicinePhysical therapyMedicine
What is this?
Publications 366
#1Iqbal Ike K. Ahmed (U of T: University of Toronto)H-Index: 30
#2Dominik Podbielski (U of S: University of Saskatchewan)H-Index: 1
Last. Ron Goeree (McMaster University)H-Index: 46
view all 7 authors...
Abstract Purpose To assess from the Canadian public payer perspective the cost-utility of implanting iStent Inject® trabecular bypass stent (TBS) devices in conjunction with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma (OAG) and visually significant cataract. Design Cost-utility analysis using efficacy and safety results of pivotal randomized clinical trial. Participants Modeled cohort of patients with OAG (83.1% mild, 16.9% moderate) and visually significa...
#1L Pericleous (Amgen)H-Index: 2
#2Mo Amin (Amgen)H-Index: 1
Last. Ron Goeree (McMaster University)H-Index: 46
view all 3 authors...
AbstractBackground: Both public and private insurers provide drug coverage in Canada. All payers are under pressure to contain costs. It has recently been proposed that private plans leverage the public health technology assessment (HTA) evaluation process in their decision-making.Objectives: The objectives of the current study were to examine use of public health technology assessments (HTAs) for private payer decision-making in the literature, to gather the perspectives of experts from both pu...
#1Vardhaman PatelH-Index: 1
#2Ike AhmedH-Index: 1
Last. Ron Goeree (McMaster University)H-Index: 46
view all 6 authors...
AbstractObjectives: To estimate the cost-utility of two trabecular micro-bypass stents (TBS) implantation vs standard of care (SOC) in patients with mild-to-moderate open-angle glaucoma (OAG) in th...
2 CitationsSource
#1Ron Goeree (McMaster University)H-Index: 46
#2Sima Chiva-Razavi (Novartis)H-Index: 2
Last. Steffen Jugl (Novartis)H-Index: 5
view all 5 authors...
AbstractAim: To assess the cost-effectiveness of interleukin (IL)-17A inhibitor secukinumab vs the currently licensed biologic therapies in ankylosing spondylitis (AS) patients from a Canadian heal...
2 CitationsSource
1 CitationsSource
#1Carita NgH-Index: 1
#2Lingyun Ye (Nova Scotia Health Authority)H-Index: 6
Last. Shelly A. McNeil (Nova Scotia Health Authority)H-Index: 34
view all 33 authors...
Background Consideration of cost determinants is crucial to inform delivery of public vaccination programs. Objectives To estimate the average total cost of laboratory-confirmed influenza requiring hospitalization in Canadians prior to, during, and 30 days following discharge. To analyze effects of patient/disease characteristics, treatment, and regional differences in costs. Methods Study utilized previously recorded clinical characteristics, resource use, and outcomes of laboratory-confirmed i...
2 CitationsSource
#1Ron Goeree (McMaster University)H-Index: 46
#2Sima Chiva-Razavi (Novartis)H-Index: 2
Last. Dafna D. Gladman (Toronto Western Hospital)H-Index: 108
view all 8 authors...
AbstractObjective: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, vs currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective.Methods: A decision analytic semi-Markov model evaluated the cost-effectiveness of secukinumab 150 mg and 300 mg compared to subcutaneous biologics adalimumab, certolizumab pegol, etanercept, golimum...
6 CitationsSource
#1Guowei Li (McMaster University)H-Index: 10
#2Robert Hopkins (McMaster University)H-Index: 18
Last. Daria O’Reilly (McMaster University)H-Index: 25
view all 9 authors...
Aims To investigate the effect of hyperbaric oxygen therapy on health-related quality of life (HRQoL) in participants with diabetes and chronic foot ulcers.
4 CitationsSource